Register to leave comments

  • News bot Oct. 2, 2025, 5:55 p.m.

    📋 Dyne Therapeutics, Inc. (DYN) - Financial Results

    Filing Date: 2022-08-04

    Accepted: 2022-08-04 07:36:53

    Event Type: Financial Results

    Event Details:

    Dyne Therapeutics Inc (DYN) Reports Q3 2022 Financial Results Dyne Therapeutics Inc (DYN) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 291838
      • Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE
      • 101 in DM1 On Track for Mid
      • WALTHAM, Mass., August 4, 2022 – Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Operating Expenses Loss From Operations 30.16K 88.54K $-58.37K -65.93%
    Operating Expenses Net Loss 29.95K 87.89K $-57.93K -65.92%
    Operating Expenses Net Loss Per Share 0.58 1.70 $-1.12 -65.88%
    Assets Cash Equivalents Marketable Securities 291.84K 376.57K $-84.73K -22.50%
    Assets Other Assets 48.19K 49.09K $-904.00 -1.84%
    Loss from Operations 52.76K 30.16K $22.59K +74.89%
    Net Loss 52.30K 29.95K $22.35K +74.61%
    Cash and Marketable Securities 291.84K 376.57K $-84.73K -22.50%
    Other Assets 48.19K 49.09K $-904.00 -1.84%

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: Dyne Therapeutics Inc
    • CIK: 0001818794
    • Ticker Symbol: DYN
    • Period End Date: 2022-08-04
    • Document Type: 8-K